@article{article_537178, title={The Utilization of Alpha-1 Anti-trypsin (A1AT) in Infectious Disease Monitoring and Treatment}, journal={Journal of Microbiology and Infectious Diseases}, volume={09}, pages={51–58}, year={2019}, DOI={10.5799/jmid.537178}, author={Indalao, İrene L. and Agustiningsih, Agustiningsih and Pratiwi, Eka and Puspa, Kartika Dewi and Ikawati, Hartanti Dian and Ramadhany, Ririn}, keywords={Alpha-1 anti-trypsin,virus,bacteria,biomarker,drug,infection,parasite,protozoa,review}, abstract={<p class="MsoNormal" style="margin-top:6pt;margin-right:0cm;margin-bottom:6pt;margin-left:0cm;text-align:justify;"> <span lang="en-us" style="font-size:9pt;line-height:107%;font-family:Arial, ’sans-serif’;" xml:lang="en-us">Alpha
one anti-trypsin (A1AT) is a major serine protease inhibitor found circulating
in human blood. A1AT related studies mainly focus on A1AT potential biomarker
as well as therapeutic target in non-infectious diseases. Their findings
indicate A1AT beneficial features may also be applied for monitoring and
treating infectious disease. However, only a few studies have reviewed A1AT’s
useful properties as a biomarker and therapeutic agent for infectious diseases.
This narrative review aims to summarize growing evidences that support the idea
of utilizing A1AT as a tool for monitoring and therapy for infectious diseases. </span> </p> <p> </p> <p class="MsoNormal" style="margin-top:6pt;margin-right:0cm;margin-bottom:6pt;margin-left:0cm;text-align:justify;"> <span lang="en-us" style="font-size:9pt;line-height:107%;font-family:Arial, ’sans-serif’;" xml:lang="en-us">A1AT
showed potential as a biomarker for a wide spectrum of infectious disease, from
virus, bacteria, to parasite. Its level and functionality were proposed to
predict risk for disease susceptibility or progression and to indicate response
therapy. As promising therapeutic agent in various infectious diseases, the
administration of A1AT has shown antimicrobial activity, immunomodulatory and
anti-apoptotic effect, in addition to more familiar function, suppressing
excessive proteolysis. </span> </p> <p> </p> <p class="MsoNormal" style="margin-top:6pt;margin-right:0cm;margin-bottom:6pt;margin-left:0cm;text-align:justify;"> <span lang="en-us" style="font-size:9pt;line-height:107%;font-family:Arial, ’sans-serif’;" xml:lang="en-us">The
broad utilization of A1AT, both as biomarker and therapeutic agent, in studies
on infectious diseases seems promising. However, there are issues need to be
investigated further before establishing its feasibility as a monitoring and
therapy tool against infection diseases </span> <span lang="en-us" style="font-size:9pt;line-height:107%;font-family:Arial, ’sans-serif’;" xml:lang="en-us">.  <i>J
Microbiol Infect Dis 2019; 9(1): 51-58. </i> </span> <i> <span lang="en-us" style="font-size:9pt;line-height:107%;font-family:Arial, ’sans-serif’;" xml:lang="en-us"> </span> </i> </p> <p> <i> </i> </p> <i> </i>}, number={01}, publisher={Aydın ECE}